TRML Tourmaline: Long-Term Debt to Capital Coefficient

The share price history of Tourmaline Bio, Inc. (TRML) on the GURU.Markets platform reflects the dynamics of a company focused on launching final antibody tests for the therapy of cardiac and ocular pathologies. The current figure is 0.00. The business relies on developing advanced thyroid treatments, strengthening its authority within the scientific community, and competing for priority in the registration of unique immune drugs.

The investment attractiveness of Tourmaline Bio, Inc. (TRML) is based on the development of breakthrough treatments for autoimmune pathologies through scientific collaborations that require significant long-term funding. The ratio compares the volume of liabilities with a maturity of over one year to equity, whereby the current long-term debt-to-equity level determines the company's resilience to refinancing risks and the fundamental independence of its R&D strategy.